Kura Oncology, Inc. (KURA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
4930 Directors Place
San Diego, CA 92121
United States of America (the)
Phone
858 500 8800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
260
First IPO Date
September 16, 2015
| Name | Title | Pay | Year Born |
| Troy Edward Wilson | Chairman, Chief Executive Officer & President | 1.44M | 1969 |
| Teresa Brophy Bair | Chief Legal Officer & Corporate Secretary | 745,021 | 1971 |
| Brian T. Powl | Chief Commercial Officer | 814,998 | 1974 |
| Mollie Leoni | Chief Medical Officer | 855,297 | 1978 |
| Kathleen Ford | Chief Operating Officer | 926,501 | 1947 |
| Roger Bakale | Senior Vice President of Manufacturing & Supply Chain | 0 | N/A |
| Francis J. Burrows | Chief Scientific Officer | 0 | 1962 |
| Thomas Doyle | Senior Vice President of Finance & Accounting | 0 | 1971 |
| Greg Mann | Senior Vice President of Investor Relations & Corporate Affairs | 0 | N/A |
| Samir Vattompadam | Senior Vice President of Global Program Leadership | 0 | N/A |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.